4.5 Article

Clinical phenotype in carriers of intermediate alleles in the huntingtin gene

期刊

JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 402, 期 -, 页码 57-61

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2019.05.010

关键词

Huntington's; CAG; Intermediate

资金

  1. Allergan, Inc.
  2. CHDI Foundation
  3. Civitas/Acorda Therapeutics
  4. Dystonia Coalition
  5. Dystonia Medical Research Foundation
  6. F. Hoffmann-La Roche Ltd.
  7. Huntington Study Group
  8. Medtronic Neuromodulation
  9. Merz Pharmaceuticals
  10. Michael J Fox Foundation for Parkinson Research
  11. National Institutes of Health
  12. Neurocrine Biosciences
  13. Parkinson's Foundation
  14. Nuvelution
  15. Parkinson Study Group
  16. Pfizer Inc.
  17. Prothena Biosciences Inc.
  18. Psyadon Pharmaceuticals, Inc.
  19. Revance Therapeutics, Inc.
  20. Teva Pharmaceutical Industries Ltd.
  21. US WorldMeds

向作者/读者索取更多资源

Objective: To describe the phenotype of individuals with intermediate allele (IA) CAG repeat length in the huntingtin (HTT) gene evaluated at the Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC) at Baylor College of Medicine (BCM). Background: Huntington disease (HD) is caused by a mutation in the HIT gene of 36 or more CAG trinucleotide repeats. Since our original case report of pathologically proven HD with 29 CAG repeats, a growing body of evidence has accumulated supporting the observation that individuals with IA (27 to 35 CAG repeats) may exhibit clinical, imaging, and pathologic manifestations of HD. About 6% of the general population has CAG repeats in the IA range in at least one allele of the HTT gene. The presence of IA is a challenge for genetic counseling. Methods: Medical records of patients with IAs seen at the PDCMDC at BCM from January 2008 to the present were reviewed to assess age at symptom onset, dominant clinical features and presence of psychiatric and cognitive symptoms. Results: Four men and five women were found to have IAs (range: 27-35) in the course of their evaluation at the PDCMDC. The age at onset of clinically evident symptoms ranged from 27 to 78 years. Six individuals had chorea, three had gait disturbance, two had stereotypies, and one patient had multiple motor tics. All nine had psychiatric symptoms, with depression being the most common. Conclusion: Our series of 9 individuals with IA in the HTT gene exhibit a variety of motor and non-motor features that overlap with the HD phenotype. These individuals and their offspring should be considered at risk for development of progressive HD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据